Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent approval. Ziihera is now available to prescribers in the U.S. at a wholesale acquisition cost price of about $35,500 for a 28-day cycle, the analyst noted. With the launch of Ziihera in biliary tract cancer and Phase 3 data in gastroesophageal adenocarcinoma due in Q2 of 2025, the firm believes the company is “well-positioned for shares to appreciate in 2025,” the analyst tells investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- ALX Oncology announces results from Phase 1b/2 trial
- Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines
- Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio
- Roche announces FDA approval of label expansion into biliary tract cancer
- FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera